Early Detection Research Network

ERBB3

Aliases:
This biomarker is also known as:
  • ERBB3,
  • Proto-oncogene-like protein c-ErbB-3,
  • erbB3-S,
  • p85-sErbB3,
  • c-erbB-3,
  • LCCS2,
  • c-erbB3,
  • HER3,
  • EC 2.7.10.1,
  • p180-ErbB3,
  • v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian),
  • p45-sErbB3,
  • Tyrosine kinase-type cell surface receptor HER3,
  • lethal congenital contracture syndrome 2,
  • MDA-BF-1,
  • tyrosine kinase-type cell surface receptor HER3,
  • ErbB-3,
  • proto-oncogene-like protein c-ErbB-3,
  • receptor tyrosine-protein kinase erbB-3,

Description…

From NCBI Gene: This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized. [provided by RefSeq, Jul 2008]

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Gene
HGNC Name: ERBB3

The following organs have data associated with this biomarker…

Attributes

Phase: One
QA State: Curated

Overview

No additional prostate data available.

Performance Comment

19 common probe sets (15 unique genes) were used to develop a PAM-based classifier, which had an average accuracy of 87% when it was tested on 47 independent tumor-adjacent stroma samples. The 15 genes represented in the classifier are: GADD45B, CDKN1A, NLRP1, ERBB3, FMO5, KIAA0746///SERINC2, AMFR, DPP4, PGC, YWHAE, EHF, TF, TNFSF10, EIF5A, TGM4. This is the first general tumor microenvironment-based prognostic classifier. Tumor-adjacent prostate cancer stroma contains numerous changes in gene expression at the time of diagnosis that correlate with the chance of relapse following prostatectomy. These results indicate that the prostate cancer microenvironment exhibits reproducible changes useful for predicting outcomes for patients.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.